News

Lung cancer screening criteria may need changes


 

FROM JAMA

References

Fewer patients diagnosed with lung cancer are meeting the U.S. Preventive Services Task Force criteria for screening with low-dose computed tomography (LDCT).

Screening criteria may need to be changed, since fewer American adults now have a smoking history of 30-pack years and have quit within the last 15 years, according to Dr. Ping Yang of the division of epidemiology at the Mayo Clinic, Rochester, Minn., and her colleagues.

©thinkstockphotos.com

A retrospective analysis of patients with pathologically confirmed lung cancer in Olmsted County, Minn., between 1984 and 2011 found that in 1984-1990, 57% of patients with diagnosed lung cancer met USPSTF screening guidelines. By 2005-2011, the figure had dropped significantly to 43%.

The proportion of women who would have been eligible under the criteria decreased from 52% to 37% in the same time period; the proportion of men had dropped from 60% to 50%, they found.

“More sensitive screening criteria may need to be identified while balancing the potential harm from computed tomography,” Dr. Yang and her colleagues wrote (JAMA 2015 Feb. 24;313:853-5).

Lung cancer incidence trends in this study were comparable with Surveillance, Epidemiology and End Results data, but may not be generalizable to the U.S. population, they added.The study was funded by the National Institutes of Health and the Mayo Clinic Foundation. The authors reported no relevant conflicts of interest.

Recommended Reading

Adding cisplatin to docetaxel monotherapy provides no benefit for elderly with NSCLC
MDedge Hematology and Oncology
Metformin linked to lower risk of lung cancer in diabetic nonsmokers
MDedge Hematology and Oncology
Lung cancer bypasses breast cancer as leading cause of cancer death for women in developed countries
MDedge Hematology and Oncology
Medicare now covers low-dose CT screen for lung cancer
MDedge Hematology and Oncology
NSCLC meta-analysis shows strong link between ORR, PFS
MDedge Hematology and Oncology
PORT boosts survival in N2 NSCLC patients
MDedge Hematology and Oncology
Crizotinib strikingly effective for advanced ROS1-positive NSCLC
MDedge Hematology and Oncology
Cancer mortality lowest in western United States
MDedge Hematology and Oncology
More cancer patients surviving longer, but age-based disparities remain
MDedge Hematology and Oncology
Baseline QOL measures not associated with outcomes in high-risk operable lung cancer patients
MDedge Hematology and Oncology